ArticleGastroenterology2010
Affinity peptide for targeted detection of dysplasia in Barrett's esophagus.
Article in Gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 93 citations in OpenAlex.
- Article
- Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes.European journal of nuclear medicine and molecular imaging · 2023Article
- Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.Diagnostics (Basel, Switzerland) · 2022Review
- A CD10-OGP Membrane Peptolytic Signaling Axis in Fibroblasts Regulates Lipid Metabolism of Cancer Stem Cells via SCD1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Targeted imaging of esophageal adenocarcinoma with a near-infrared fluorescent peptide.BMC gastroenterology · 2021Article
- Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging.Cellular and molecular bioengineering · 2020Review
- Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet.Scientific reports · 2019Article
- An adhesion based approach for the detection of esophageal cancer.Integrative biology : quantitative biosciences from nano to macro · 2018Article
- Selection and identification of novel peptides specifically targeting human cervical cancer.Amino acids · 2018Article
- Validation of near infrared fluorescence (NIRF) probes in vivo with dual laser NIRF endoscope.PloS one · 2018Article
- Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications.Contrast media & molecular imaging · 2018Review
- Computational Analysis on Down-Regulated Images of Macrophage Scavenger Receptor.Pharmaceutical research · 2017Article
- A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer.Oncotarget · 2017Article
- Detection of Sessile Serrated Adenomas in the Proximal Colon Using Wide-Field Fluorescence Endoscopy.Gastroenterology · 2017Article
- Endoscopic modalities for the diagnosis of Barrett's oesophagus.United European gastroenterology journal · 2016Review
- Depth-resolved imaging of colon tumor using optical coherence tomography and fluorescence laminar optical tomography.Biomedical optics express · 2016Article
- Barrett's esophagus in 2016: From pathophysiology to treatment.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Overexpressed Claudin-1 Can Be Visualized Endoscopically in Colonic Adenomas In Vivo.Cellular and molecular gastroenterology and hepatology · 2016Article
- Wireless fluorescence capsule for endoscopy using single photon-based detection.Scientific reports · 2015Article
- EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging.Clinical and translational gastroenterology · 2015Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsDysplasia is a premalignant condition in Barrett's esophagus that is difficult to detect on endoscopy because of its flat architecture and patchy distribution. Peptides are promising for use as novel molecular probes that identify cell surface targets unique to disease and can be fluorescence-labeled for detection. We aim to select and validate an affinity peptide that binds to esophageal dysplasia for future clinical studies.
methodsPeptide selection was performed using phage display by removing nonspecific binders using Q-hTERT (intestinal metaplasia) cells and achieving specific binding against OE33 (esophageal adenocarcinoma) cells. Selective binding was confirmed on bound phage counts, enzyme-linked immunosorbent assay (ELISA), flow cytometry, competitive inhibition, and fluorescence microscopy. On stereomicroscopy, specific peptide binding to dysplasia on endoscopically resected specimens was assessed by rigorous registration of fluorescence intensity to histology in 1-mm intervals.
resultsThe peptide sequence SNFYMPL was selected and showed preferential binding to target cells. Reduced binding was observed on competition with unlabeled peptide in a dose-dependent manner, an affinity of K(d) = 164 nmol/L was measured, and peptide binding to the surface of OE33 cells was validated on fluorescence microscopy. On esophageal specimens (n = 12), the fluorescence intensity (mean ± SEM) in 1-mm intervals classified histologically as squamous (n = 145), intestinal metaplasia (n = 83), dysplasia (n = 61), and gastric mucosa (n = 69) was 46.5 ± 1.6, 62.3 ± 5.8, 100.0 ± 9.0, and 42.4 ± 3.0 arb units, respectively.
conclusionsThe peptide sequence SNFYMPL binds specifically to dysplasia in Barrett's esophagus and can be fluorescence labeled to target premalignant mucosa on imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.